Detection of antibodies against benzo[a]pyrene in blood sera of lung cancer patients by ELISA using human recombinant idiotypic and anti-idiotypic antibodies.

Q3 Medicine

Experimental oncology Pub Date : 2021-12-01 DOI:10.32471/exp-oncology.2312-8852.vol-43-no-4.17126

A E Studennikov, A N Glushkov, V A Ustinov

{"title":"Detection of antibodies against benzo[a]pyrene in blood sera of lung cancer patients by ELISA using human recombinant idiotypic and anti-idiotypic antibodies.","authors":"A E Studennikov, A N Glushkov, V A Ustinov","doi":"10.32471/exp-oncology.2312-8852.vol-43-no-4.17126","DOIUrl":null,"url":null,"abstract":"Aim of this study was to develop and apply an ELISA method for assessment of the levels of endogenous antibodies against benzo[a]pyrene (Bp) in blood sera of lung cancer (LC) patients.Materials and methods: ELISA was developed and applied for the detection of endogenous idiotypic and anti-idiotypic antibodies against Bp in human blood sera using recombinant human idiotypic and anti-idiotypic antibodies against Bp.Results: Serum samples of LC patients (n = 22) and healthy donors (n = 24) were analyzed by the new method. Statistical analysis showed that in sera of LC patients the levels of endogenous idiotypic and anti-idiotypic antibodies against Bp were significantly higher than in healthy donors. A logistic regression model for the LC detection utilizing such predictors as the serum levels of idiotypic and anti-idiotypic antibodies against Bp, smoking status, and age, identified LC patients with 83% specificity and 82% sensitivity.Conclusion: The proposed method could be further developed as additional lung cancer screening tool.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"43 4","pages":"322-327"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim of this study was to develop and apply an ELISA method for assessment of the levels of endogenous antibodies against benzo[a]pyrene (Bp) in blood sera of lung cancer (LC) patients.

Materials and methods: ELISA was developed and applied for the detection of endogenous idiotypic and anti-idiotypic antibodies against Bp in human blood sera using recombinant human idiotypic and anti-idiotypic antibodies against Bp.

Results: Serum samples of LC patients (n = 22) and healthy donors (n = 24) were analyzed by the new method. Statistical analysis showed that in sera of LC patients the levels of endogenous idiotypic and anti-idiotypic antibodies against Bp were significantly higher than in healthy donors. A logistic regression model for the LC detection utilizing such predictors as the serum levels of idiotypic and anti-idiotypic antibodies against Bp, smoking status, and age, identified LC patients with 83% specificity and 82% sensitivity.

Conclusion: The proposed method could be further developed as additional lung cancer screening tool.

查看原文本刊更多论文

人重组独特型和抗独特型抗体ELISA检测肺癌患者血清中苯并[a]芘抗体

本研究的目的是建立和应用ELISA方法评估肺癌(LC)患者血清中抗苯并[a]芘(Bp)的内源性抗体水平。材料和方法:采用重组人抗Bp独特型抗体和抗独特型抗体，建立ELISA法检测人血清中内源性Bp独特型和抗独特型抗体。结果:采用新方法分析了LC患者(22例)和健康供者(24例)的血清样本。统计分析表明，LC患者血清中抗Bp的内源性独特型和抗独特型抗体水平明显高于健康供者。利用血清中抗Bp独特型和抗独特型抗体水平、吸烟状况和年龄等预测因子，LC检测的逻辑回归模型识别出LC患者的特异性为83%，敏感性为82%。结论:该方法可作为肺癌筛查的辅助手段进一步发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.